Investment fund buys stake in Rwandan firm
Stocks & Markets
By
-
| Jan 23, 2013
By John Oyuke
Kenyan-based venture capital fund, Fanisi Capital, has bought stake in a Rwandan pharmaceutical firm, Sophar Limited.
The investment in the Kigali-based company, which imports branded drugs, mostly from Europe and sells in Rwanda, represents a key milestone for the $50 million (Sh4.35 billion) equity fund as it is the first investment outside the country.
Though Fanisi did not disclose the amount invested, citing non-disclosure agreements with the drugs wholesaler, the fund usually make investments with initial values of between $1 and $3 million (approximately Sh87m and Sh261m).
Announcing the investment in Nairobi, the co-Managing Partner of Fanisi Capital, Ayisi Makatiani, said the funding, which was achieved through a mix of equity and debt, will be used to build a drugs warehouse in Kigali.
READ MORE
Kiosk economy: How small traders fuelled Safaricom's Sh100b profit
Beyond promises, budget must put money into Kenyans' pockets
Dangote favours Mombasa over Tanzania's Tanga for Sh2tr oil refinery
Pipeline politics: Why East Africa's joint refinery dream faces slippery path
Debt burden: Inside Treasury's plan to trap Kenya with billions in hidden debt
State plans major audit shakeup to stem graft, wastage of funds
Creative economy key to job creation, says PS Fikirini Jacobs
Beyond the Silicon Savannah: Why Africa's AI revolution must start 'mashinani'
He said that the new investment would significantly expand the company product range from 900 to 3,000 products within a few years, and set up distribution centres for enhanced access and improve supply chain.
“A key benefit is that the investment will allow better access to drugs, especially for the neediest sections of the population,” stressed Makatiani.